Institutional Investor

Institutional Investor Launches 2023 Developed Europe, 2023 UK Small & Midcap and 2023 Emerging Emea Research Rankings

Retrieved on: 
Wednesday, September 6, 2023

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Institutional Investor Research (II Research) surveys are the leading provider of market sentiment in the financial industry. Research budgets remain flat and asset managers are using fewer analysts, but demand for bespoke opinion means that close client relationships and “trusted source” status becomes more important than ever before. With MiFID regulations potentially being rolled back across Europe and UK, the focus on the provision of quality research advisory services may result in a more competitive environment and we may see an increase in research teams across the industry.

Key Points: 
  • NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Institutional Investor Research (II Research) surveys are the leading provider of market sentiment in the financial industry.
  • The Leaders’ Board remains intensely competitive, with seven companies competing for the honour of being rated best research house.
  • The 2023 UK Small & Midcap results reflect the opinions of 359 portfolio managers and analysts at 233 institutions.
  • The Best UK Small & Midcap Broker award represents an aggregate of all 20 research categories, plus the Sales, Corporate Access and Corporate Broking categories.

Barclays Announces New Senior Appointments in Healthcare Investment Banking and in Equity Research

Retrieved on: 
Wednesday, September 6, 2023

Barclays today announced new senior appointments in Healthcare Investment Banking and in Equity Research.

Key Points: 
  • Barclays today announced new senior appointments in Healthcare Investment Banking and in Equity Research.
  • They include the hiring of Maneet Singh and appointment of Evan Matlin as new Co-Heads of Healthcare M&A in the United States, Jon Swope joining the Healthcare Information Technology Banking team, and Stephanie Davis in Equity Research.
  • Other recent hires and appointments in Barclays’ Healthcare Investment Banking group include Jim Birchenough as Chairman of Global Healthcare Investment Banking and Co-Head of Global Biopharma Investment Banking, Alexis de Rosnay as Co-Head of Global Biopharma Investment Banking and Chairman of Global Healthcare Investment Banking, and Jeff Ammerman as Global Head of Specialty Pharmaceuticals Investment Banking.
  • Stephanie Davis will join Barclays as a Managing Director to lead Barclays’ equity research on the US Healthcare Technology & Digital Health sector.

EC Healthcare Received "Institutional Investor" 2023 Multiple Awards in All-Asia Executive Team Rankings

Retrieved on: 
Wednesday, June 21, 2023

HONG KONG, June 21, 2023 - (ACN Newswire) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce the excellent result in the "All-Asia Executive Team Rankings 2023" under the category of Healthcare, Pharma & Biotech organized by Institutional Investor, an international magazine.

Key Points: 
  • HONG KONG, June 21, 2023 - (ACN Newswire) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce the excellent result in the "All-Asia Executive Team Rankings 2023" under the category of Healthcare, Pharma & Biotech organized by Institutional Investor, an international magazine.
  • The Group is delighted recognize as The Most Honoured Company (Healthcare, Pharma & Biotech) in the division - Mid & Smallcap and Asia (excluding mainland China), which represents recognition of the Group's impressive performance by the investors and the market.
  • Recognized as an authoritative ranking by industries, "All-Asia Executive Team Rankings" celebrates the outstanding companies and management teams in Asia.
  • Buy-side and sell-side analysts rated the listed companies within the scope of their research according to several criteria used in evaluating performance in corporate governance.

BTG Pactual reports all-time high net income supported by another quarter of record revenues and 22.7% ROAE

Retrieved on: 
Wednesday, August 9, 2023

SÃO PAULO, Aug. 9, 2023 /PRNewswire/ -- BTG Pactual (BPAC11) posted another quarter of record revenue and net income. Revenue closed Q2 at R$5.4bn, up 21% y/y, while adjusted net income was R$2.6bn, up 18% y/y. ROAE totaled 22.7%, the highest since 2015. Without the accounting impact of the Banco PAN credit portfolio acquisition, ROAE would have been 25.2%.

Key Points: 
  • Strong net new money of R$61 billion, totaling R$1.4 trillion AuM/WuM
    SÃO PAULO, Aug. 9, 2023 /PRNewswire/ -- BTG Pactual (BPAC11) posted another quarter of record revenue and net income.
  • "We closed the quarter with record revenue and net income in a challenging macroeconomic scenario, demonstrating the resilience and diversification of our business.
  • Net new money of R$61bn proved once again the quality of our franchises and of our network, totaling R$1.4tn in AuM/AuA.
  • BTG Pactual raised R$61bn in Net New Money (NNM), with R$35.4bn in Wealth Management and R$25.4bn in Asset Management.

BTG Pactual reports all-time high net income supported by another quarter of record revenues and 22.7% ROAE

Retrieved on: 
Wednesday, August 9, 2023

SÃO PAULO, Aug. 9, 2023 /PRNewswire/ -- BTG Pactual (BPAC11) posted another quarter of record revenue and net income. Revenue closed Q2 at R$5.4bn, up 21% y/y, while adjusted net income was R$2.6bn, up 18% y/y. ROAE totaled 22.7%, the highest since 2015. Without the accounting impact of the Banco PAN credit portfolio acquisition, ROAE would have been 25.2%.

Key Points: 
  • Strong net new money of R$61 billion, totaling R$1.4 trillion AuM/WuM
    SÃO PAULO, Aug. 9, 2023 /PRNewswire/ -- BTG Pactual (BPAC11) posted another quarter of record revenue and net income.
  • "We closed the quarter with record revenue and net income in a challenging macroeconomic scenario, demonstrating the resilience and diversification of our business.
  • Net new money of R$61bn proved once again the quality of our franchises and of our network, totaling R$1.4tn in AuM/AuA.
  • BTG Pactual raised R$61bn in Net New Money (NNM), with R$35.4bn in Wealth Management and R$25.4bn in Asset Management.

Banorte, with Carlos Hank González and his Board of Directors, Named Best in the Financial Sector in Latin America by Institutional Investor

Retrieved on: 
Tuesday, August 8, 2023

For the first time, the category of Best Company Board of Directors is evaluated as part of the ranking, and GFNorte takes the first place in the ranking.

Key Points: 
  • For the first time, the category of Best Company Board of Directors is evaluated as part of the ranking, and GFNorte takes the first place in the ranking.
  • In Mexico, considering companies from all sectors, Grupo Financiero Banorte is recognized for the second consecutive year as the Most Honored Company.
  • Grupo Financiero Banorte (GFNorte) secured the top position in all categories of the ranking for financial companies in Latin America (excluding Brazil, according to Institutional Investor's methodology).
  • Furthermore, GFNorte received recognition as the Best Company Board of Directors in the financial sector in Latin America, with Carlos Hank González as their Chairman.

Infosys: Solid Q1 year on year revenue growth of 4.2% at 20.8% operating margins

Retrieved on: 
Thursday, July 20, 2023

BENGALURU, India, July 20, 2023 /PRNewswire/ -- Infosys (NSE: INFY), (BSE: INFY), (NYSE:INFY), a global leader in next-generation digital services and consulting, delivered $4,617 million in Q1 revenues with year on year growth of 4.2% and sequential growth of 1.0% in constant currency. Large deal TCV for the quarter was at $2.3 billion, with net new of 56.1%. Operating margin for the quarter was stable at 20.8%. ROE improved 180 bps to 32.8%. Attrition declined further to 17.3%. FY24 revenue guidance revised to 1.0%-3.5% and operating margin guidance retained at 20%-22%.

Key Points: 
  • Company's rigorous operational discipline including improved productivity measures and higher utilization helped margins for the quarter," said Nilanjan Roy, CFO.
  • Danske Bank recently signed a strategic collaboration with Infosys to accelerate the bank's digital transformation initiatives with speed and scale.
  • Infosys has the tools, experience, and expertise to support us in accelerating our transformation using cloud and AI technologies.
  • Together, we look forward to delivering innovative solutions that meet the evolving needs of our customers and drive growth for the future."

Infosys: Solid Q1 year on year revenue growth of 4.2% at 20.8% operating margins

Retrieved on: 
Thursday, July 20, 2023

BENGALURU, India, July 20, 2023 /PRNewswire/ -- Infosys (NSE: INFY), (BSE: INFY), (NYSE:INFY), a global leader in next-generation digital services and consulting, delivered $4,617 million in Q1 revenues with year on year growth of 4.2% and sequential growth of 1.0% in constant currency. Large deal TCV for the quarter was at $2.3 billion, with net new of 56.1%. Operating margin for the quarter was stable at 20.8%. ROE improved 180 bps to 32.8%. Attrition declined further to 17.3%. FY24 revenue guidance revised to 1.0%-3.5% and operating margin guidance retained at 20%-22%.

Key Points: 
  • Company's rigorous operational discipline including improved productivity measures and higher utilization helped margins for the quarter," said Nilanjan Roy, CFO.
  • Danske Bank recently signed a strategic collaboration with Infosys to accelerate the bank's digital transformation initiatives with speed and scale.
  • Infosys has the tools, experience, and expertise to support us in accelerating our transformation using cloud and AI technologies.
  • Together, we look forward to delivering innovative solutions that meet the evolving needs of our customers and drive growth for the future."

Treace Appoints Julie Dewey as Chief Communications and Investor Relations Officer

Retrieved on: 
Wednesday, July 12, 2023

“Julie is a talented and well-respected corporate communications leader who we are thrilled to welcome to Treace,” said John T. Treace, CEO, Founder and Board Member of Treace.

Key Points: 
  • “Julie is a talented and well-respected corporate communications leader who we are thrilled to welcome to Treace,” said John T. Treace, CEO, Founder and Board Member of Treace.
  • Prior to Nevro, she was Senior Vice President and Chief Communications Officer of Wright Medical Group, N.V., a leading orthopaedic company focused on extremities and biologics, which was acquired by Stryker.
  • While at Wright, she built a world-class investor relations program that was the highest ranked small-mid cap medical device IR program by Institutional Investor for a record five consecutive years.
  • Earlier in her career, Ms. Dewey held investor relations and marketing positions at ev3 Inc. (acquired by Covidien/Medtronic), Kyphon Inc. (acquired by Medtronic) and Thoratec Corporation (acquired by St. Jude/Abbott).

Coherent Appoints Paul Silverstein as VP, Investor Relations & Corporate Communications

Retrieved on: 
Tuesday, July 11, 2023

PITTSBURGH, July 11, 2023 (GLOBE NEWSWIRE) -- Coherent Corp. (NYSE: COHR), a global leader in materials, networking, and laser technology, today announced that Paul Silverstein has been appointed as Vice President, Investor Relations & Corporate Communications, reporting to Chair and CEO Dr. Vincent D. Mattera, Jr.

Key Points: 
  • PITTSBURGH, July 11, 2023 (GLOBE NEWSWIRE) -- Coherent Corp. (NYSE: COHR), a global leader in materials, networking, and laser technology, today announced that Paul Silverstein has been appointed as Vice President, Investor Relations & Corporate Communications, reporting to Chair and CEO Dr. Vincent D. Mattera, Jr.
    “The appointment of Paul Silverstein to head up our investor relations and corporate communications teams is the next step in expanding our brand recognition with a renewed focus on investors,” said Dr. Mattera.
  • “Paul will play a pivotal role in representing our company to the investment community.
  • Most recently, he spent the past 10 years as a managing director and senior analyst at Cowen Inc.
  • Prior to his career in equity research, he practiced corporate and securities law as an associate at Pryor Cashman Sherman & Flynn and at Weil, Gotshal & Manges.